Abstract library

31 results for "Rose".
#725 Contrast-Enhanced Ultrasonography (CEUS) Predicts the Effectiveness of Anti-Angiogenic Therapies in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Liver metastases (LM) from neuroendocrine tumors (NETs) exhibit a typical hypervascular pattern in the arterial phase on CEUS, allowing for a differential diagnosis between NET and non-NET LM. Medical therapy includes agents acting on angiogenesis and vascularization which may result in a change in CEUS findings.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Antonella Di Sarno
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)
Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Francesca Marciello
#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#1310 Current Trials in Neuroendocrine Tumours: A Systematic Review
Introduction: Trials in neuroendocrine tumours (NETs) have increased markedly in number over the last 10 years. Researchers do not have ready access to a summary of open trials to identify research gaps.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Segelov E, Millican J, Singh S, ...
Keywords: trials, review
#1638 3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuro-Endocrine Tumors (pNETs).
Introduction: The lack of adequate in vitro and in vivo preclinical models has hampered the identification of novel treatment options and the development of personalized therapy selection for pNET patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ilaria Marinoni
#110 Slug represents an important regulator of E-cadherin expression in neuroendocrine tumor cells of the pancreas
Introduction: Neuroendocrine tumors of the pancreas form an inhomogenous group of epithelial neoplasms. They differ from other types of pancreatic cancers by showing an extended survival of patients, which is due to a mostly slow proliferation rate of the tumor. However, some of these neuroendocrine tumors are characterized by an early onset of metastases, which cannot be predicted by any available method. The epithelial to mesenchymal transition (EMT) represents a central part of cell migration and metastasis. During EMT, cells loosen their cellular contacts, leave the tissue, and become migrating single cells. One of the integral compounds of cell adhesion represents the E-cadherin adhesion module, which contains mostly E-cadherin and several catenins. A loss of this adhesion module is associated with tumor progression, migration and metastasis in many types of cancer.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Alexander König
#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Carlos A. S. Soares
#421 Pelvic Carcinoid Tumor Recurrence Treated by Laparosocopic Ultrasonography Guided Laparoscopic Resection
Introduction: Minute retroperitoneal carcinoid tumor recurrences may be difficult to locate during surgery. A laparoscopic approach to re-resection is further hampered by the lack of tactile sense. Laparoscopic Ultrasonography (LUS) is a minimally invasive method which may compensate for the lack of palpation during laparoscopic surgery, and LUS allows for an evaluation of lesions beneath the visible surfaces. LUS is used in the pretherapeutic staging of upper GI tract cancer, and LUS can identify - and if necessary also biopsy - lesions less than 10 mm in diameter.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Henning O Nielsen
Authors: Nielsen H O, Mortensen M B, ...
#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models
Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Carleen Cullinane
Authors: Cullinane C, Waldeck K, Kirby L, Eu P, ...